Profile of perampanel and its potential in the treatment of partial onset seizures

Sylvain Rheims,1,2 Philippe Ryvlin1,21Department of Functional Neurology and Epileptology and Institute for Children and Adolescent with Epilepsy, Hospices Civils de Lyon, Lyon, France; 2Lyon Neuroscience Research Center, INSERM U1028 / CNRS UMR 5292 Translational and Integrative Group in Epilepsy R...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rheims S, Ryvlin P
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/0ed2f0ce0ec946d68d03fec11c339d09
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0ed2f0ce0ec946d68d03fec11c339d09
record_format	dspace
spelling	oai:doaj.org-article:0ed2f0ce0ec946d68d03fec11c339d092021-12-02T01:11:43ZProfile of perampanel and its potential in the treatment of partial onset seizures1176-63281178-2021https://doaj.org/article/0ed2f0ce0ec946d68d03fec11c339d092013-05-01T00:00:00Zhttp://www.dovepress.com/profile-of-perampanel-and-its-potential-in-the-treatment-of-partial-on-a13028https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Sylvain Rheims,1,2 Philippe Ryvlin1,21Department of Functional Neurology and Epileptology and Institute for Children and Adolescent with Epilepsy, Hospices Civils de Lyon, Lyon, France; 2Lyon Neuroscience Research Center, INSERM U1028 / CNRS UMR 5292 Translational and Integrative Group in Epilepsy Research, Lyon, FranceAbstract: Perampanel (PER) is a novel antiepileptic compound that decreases neuronal excitability by modulating glutamatergic transmission through selective noncompetitive blockade of AMPA receptors. PER has been evaluated in three pivotal placebo-controlled randomized trials as adjunctive therapy in adult drug-resistant partial epilepsy. In comparison to placebo, adjunctive PER effectively reduces seizure frequency. The relative risk of the responder rate (95% confidence interval [CI]) was thus 1.60 (1.08–2.36), 1.79 (1.42–2.25) and 1.66 (1.24–2.23) for once-daily PER 4 mg/day, 8 mg/day and 12 mg/day, respectively. The most common adverse events associated with PER were nonspecific central nervous system side effects. Some concerns have been raised about risk of clinically significant weight gain and of psychiatric adverse events. Long-term open-label extensions of the three pivotal trials are underway. PER has recently been approved both in Europe and in the USA for the adjunctive treatment of partial onset seizures in patients aged 12 years and above. However, in the absence of a direct comparison between PER and other licensed antiepileptic drugs’ efficacy and tolerability, the clinical advantages of PER over the other drugs in intractable partial epilepsy remains to be determined.Keywords: perampanel, epilepsy, antiepileptic drug, partial seizuresRheims SRyvlin PDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2013, Iss default, Pp 629-637 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Rheims S Ryvlin P Profile of perampanel and its potential in the treatment of partial onset seizures
description	Sylvain Rheims,1,2 Philippe Ryvlin1,21Department of Functional Neurology and Epileptology and Institute for Children and Adolescent with Epilepsy, Hospices Civils de Lyon, Lyon, France; 2Lyon Neuroscience Research Center, INSERM U1028 / CNRS UMR 5292 Translational and Integrative Group in Epilepsy Research, Lyon, FranceAbstract: Perampanel (PER) is a novel antiepileptic compound that decreases neuronal excitability by modulating glutamatergic transmission through selective noncompetitive blockade of AMPA receptors. PER has been evaluated in three pivotal placebo-controlled randomized trials as adjunctive therapy in adult drug-resistant partial epilepsy. In comparison to placebo, adjunctive PER effectively reduces seizure frequency. The relative risk of the responder rate (95% confidence interval [CI]) was thus 1.60 (1.08–2.36), 1.79 (1.42–2.25) and 1.66 (1.24–2.23) for once-daily PER 4 mg/day, 8 mg/day and 12 mg/day, respectively. The most common adverse events associated with PER were nonspecific central nervous system side effects. Some concerns have been raised about risk of clinically significant weight gain and of psychiatric adverse events. Long-term open-label extensions of the three pivotal trials are underway. PER has recently been approved both in Europe and in the USA for the adjunctive treatment of partial onset seizures in patients aged 12 years and above. However, in the absence of a direct comparison between PER and other licensed antiepileptic drugs’ efficacy and tolerability, the clinical advantages of PER over the other drugs in intractable partial epilepsy remains to be determined.Keywords: perampanel, epilepsy, antiepileptic drug, partial seizures
format	article
author	Rheims S Ryvlin P
author_facet	Rheims S Ryvlin P
author_sort	Rheims S
title	Profile of perampanel and its potential in the treatment of partial onset seizures
title_short	Profile of perampanel and its potential in the treatment of partial onset seizures
title_full	Profile of perampanel and its potential in the treatment of partial onset seizures
title_fullStr	Profile of perampanel and its potential in the treatment of partial onset seizures
title_full_unstemmed	Profile of perampanel and its potential in the treatment of partial onset seizures
title_sort	profile of perampanel and its potential in the treatment of partial onset seizures
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/0ed2f0ce0ec946d68d03fec11c339d09
work_keys_str_mv	AT rheimss profileofperampanelanditspotentialinthetreatmentofpartialonsetseizures AT ryvlinp profileofperampanelanditspotentialinthetreatmentofpartialonsetseizures
_version_	1718403239032913920

Profile of perampanel and its potential in the treatment of partial onset seizures

Ejemplares similares